Answer
Alemtuzumab has an approximate alpha half-life of 4–5 days in patients with relapsing-remitting multiple sclerosis, comparable between treatment courses.
Sources for this answer
- LEMTRADA 12 mg concentrate for solution for infusionSANOFI · emc · SmPC §5.2 Pharmacokinetic properties · Version 3Document updated
Sources checked